Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Statins 'may curb prostate cancer', suggests lab trial

  • Comment

Cholesterol-lowering statins may curb the spread of prostate cancer by interfering with the ability of tumour cells to squeeze into bones, UK research has shown.

In laboratory experiments, scientists found that statins helped to stop cancer cells change shape and invade bone marrow.

“We will watch the next stages of the research with great interest”

Iain Frame

The same tests highlighted the role of an animal fat compound in attracting prostate cancer to the bones.

Arachidonic acid (AA), a type of omega-6 fatty acid found in meat and fish, is concentrated in the bone marrow and known to promote the spread of prostate cancer.

Scientists conducting the new study discovered that cancer cells exposed to AA became rounder in shape and sprouted projections which helped them squeeze through gaps in surrounding tissue.

Treating the cells with statins prevented them morphing in this way, according to findings published in the British Journal of Cancer.

The drugs targeted a biochemical pathway both linked to AA’s effect on the cells and high cholesterol.

Study leader Professor Noel Clarke, from the University of Manchester, said: “Understanding this process will provide vital clues as to how drugs like statins might benefit certain groups of prostate cancer patients who are more at risk of their cancer spreading.”

Prostate cancer

Noel Clarke

Dr Iain Frame, director of research at Prostate Cancer UK, said: “Looking for improved ways to treat prostate cancer cells after they leave the gland is one of the key challenges we face in tackling advanced disease.

“Men at that stage of prostate cancer have far too few treatment options, and frankly deserve better,” he said.

“It’s too early to tell conclusive results about the links between cholesterol and advanced prostate cancer from this study but it’s only through research like this that better treatments will be developed,” he added.

“We will watch the next stages of the research with great interest.”


  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.